It's about time - directing our attention toward modifying the course of COPD

Respiratory Medicine

Volumn 102, Issue SUPPL. 1, 2008, Pages

  Cazzola, Mario ^a   Hanania, Nicola A ^b   Jones, Paul W ^c   Mahler, Donald A ^d   Make, Barry ^e   Ohar, Jill ^f   Rennard, Stephen ^g  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^e NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bronchodilators; Chronic obstructive; corticosteroids; Formoterol; Inhaled; Outcomes; pulmonary disease; Salmeterol; Smoking cessation; Therapy; Tiotropium

Indexed keywords

AMFEBUTAMONE; AMINOPHYLLINE; BAMBUTEROL; BAMIFYLLINE; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BITOLTEROL; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLENBUTEROL; DIPROPHYLLINE; FENOTEROL; FENOTEROL PLUS IPRATROPIUM BROMIDE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; ISOETARINE; LEVALBUTEROL; ORCIPRENALINE; OXITROPIUM BROMIDE; PIRBUTEROL; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; VARENICLINE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DYSPNEA; EXERCISE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; MORTALITY; MUSCLE WEAKNESS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SMOKING CESSATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES;

BRONCHODILATOR AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 45849109959     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(08)70006-4     Document Type: Article

References (86)

1. Anthonisen N., Connett J., Kiley J., Altose M., Bailey W., Buist A., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272 19 (1994) 1497-1505
2. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343 26 (2000) 1902-1909
3. Mokdad Ali H., Marks J.S., Stroup D.F., and Gerberding J.L. Actual Causes of Death in the United States, 2000. JAMA 291 (March 10, 2004) 10 1238-1245.
4. American Cancer Society: Cigarette Smoking, Prevention and Early Detection. ACS Cancer Facts & Figures 2006. February 13 2006 edition.
5. Schroeder S.A. What to do with a Patient who Smokes. JAMA 294 (July 27, 2005) 4 482-487.
6. Anderson J.E., Jorenby D.E., Scott W.J., and Fiore M.C. Treating Tobacco Use and Dependence: An evidence-Based Clinical Practice Guideline for Tobacco Cessation. Chest 121 (March 2002) 932-941 3:
7. Sachs D.P.L. Tobacco Dependence Treatment: Time to Change the Paradigm. Chest 129 4 (April 2006) 836-838
8. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., Billing C.B., Gong J., Reeves K.R., and for the Varencicline Phase 3 Study Group. JAMA 296 1 (July 5, 2006) 56-63
9. Gonzales D., Rennard S.I., Nides M., On-cken C., Azoulay S., Billing C.B., Watsky E.J., Gong J., Williams K.E., Reeves K.R., and for the Varenicline Phase 3 Study Group. JAMA 296 1 (July 5, 2006) 47-55
10. Klesges R.C., Johnson K.C., and Somes G. Vareni-cline for Smoking Cessation: Definite Promise, but no Panacea. JAMA 296 1 (July 5, 2006) 94-95
11. Bars M.P., Banauch G.I., Appel D., Andreachi M., Mouren P., Kelly K.J., and Prezant D.J. Tobacco Free with FDNY: The New York City Fire Department World Trade Center Tobacco Cessation Study. Chest 129 4 (April 2006) 979-987
12. Hays J.T., Hurt R.D., Rigotti N.A., Niaura R., Gonzales D., Durcan M.J., Sachs D.P., Walter T.D., Buist A.S., Johnston J.A., and White J. Sustained-Release Bupropion for Pharmacologic Relapse Prevention after Smoking Cessation. Annals of Internal Medicine 135 6 (September 2001) 423-433
13. Tonstad S., Tonnesen P., Hajek P., Williams K.E., Billing C.B., Reeves K.R., and for the Varenicline Phase 3 Study Group. JAMA 296 1 (July 5 2006) 64-71
14. Etter J., and Perneger T. Effectiveness of a Computer-tailored Smoking Cessation Program:a Randomized Trial. Arch Intern Med 161 21 (2001, Nov 26) 2596-2601
15. Etter J.-F., and Perneger T.V. Post-intervention Effect of a Computer Tailored Smoking Cessation Programme. J Epidemial Community Health 58 (2004) 849-851
16. Strecher V., Shiffman S., and West R. Addiction 100 5 (2005 May) 682-688
17. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report, Cigarette Smoking Among Adults - United States, 2004, November 11, 2005.
18. Schroeder S.A. What to do With a Patient who Smokes. JAMA 294 4 (July 27, 2005) 482-487
19. Celli B., MacNee W., and ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 6 (2004) 932-946
20. Fabbri L., Hurd S., and GOLD Scientific Committee. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. J COPD 1 (2004) 105-141
21. Executive Summary: Canadian throacic society recommendations for management of chronic obstructive pulmonary disease - 2003. Can Respir J 10 suppl a (2003) 5a-58a
22. Calverley P., and Koulouris N. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 25 1 (2005) 186-199
23. O'Donnell D., Revill S., and Webb K. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 5 (2001) 770-777
24. Tremblay L., Valenza F., Ribeiro S., Li J., and Slutsky A. Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest 99 5 (1997) 944-952
25. Vassilakopoulos T., Zakynthinos S., and Roussos C. Strenuous resistive breathing induces proinflammatory cytokines and stimulates the HPA axis in humans. Am J Physiol 277 4 Pt 2 (1999) R1013-R1019
26. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 342 18 (2000) 1301-1308
27. Ayers M., Mejia R., Ward J., Lentine T., and Mahler D. Effectiveness of salmeterol versus ipratropium bromide on exer-tional dyspnoea in COPD. Eur Respir J 17 6 (2001) 1132-1137
28. Belman M., Botnick W., and Shin J. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153 3 (1996) 967-975
29. Boni E., Corda L., Franchini D., Chiroli P., Damiani G., Pini L., et al. Volume effect and exertional dyspnoea after bron-chodilator in patients with COPD with and without expiratory flow limitation at rest. Thorax 57 6 (2002) 528-532
30. Maltais F., Hamilton A., Marciniuk D., Hernandez P., Sciurba F., Richter K., et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 128 3 (2005) 1168-1178
31. Newton M., O'Donnell D., and Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 121 4 (2002) 1042-1050
32. O'Donnell D., Fluge T., Gerken F., Hamilton A., Webb K., Aguilaniu B., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 6 (2004) 832-840
33. O'Donnell D., Voduc N., Fitzpatrick M., and Webb K. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 24 1 (2004) 86-94
34. O'Donnell D., Sciurba F., Celli B., Mahler D., Webb K., Kalberg C., et al. effect of Fluticasone Propi-onate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD. Chest 130 3 (2006) 647-656
35. Di Marco F., Milic-Emili J., Boveri B., Carlucci P., Santus P., Casanova F., et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 21 1 (2003) 86-94
36. Palange P., Valli G., Onorati P., Antonucci R., Paoletti P., Rosato A., et al. Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity in COPD patients. J Appl Physiol 97 5 (2004) 1637-1642
37. Eves N., Petersen S., Haykowsky M., Wong E., and Jones R. Helium-hyperoxia, exercise, and respiratory mechanics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174 7 (2006) 763-771
38. Somfay A., Porszasz J., Lee S., and Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 18 1 (2001) 77-84
39. Porszasz J., Emtner M., Goto S., Somfay A., Whipp B., and Casaburi R. Exercise training decreases ventila-tory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest 128 4 (2005) 2025-2034
40. Fishman A., Martinez F., Naunheim K., Piantadosi S., Wise R., Ries A., et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 348 21 (2003) 2059-2073
41. Naunheim K., Wood D., Mohsenifar Z., Sternberg A., Criner G., DeCamp M., et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 82 2 (2006) 431-443
42. Martinez F., de Oca M., Whyte R., Stetz J., Gay S., and Celli B. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 155 6 (1997) 1984-1990
43. Hopkinson N., Toma T., Hansell D., Goldstraw P., Mox-ham J., Geddes D., et al. Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med 171 5 (2005) 453-460
44. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 93 3 (1980) 391-398
45. Calverley P., Anderson J., Celli B., Ferguson G., Jenkins C., Jones P., Yates J., Vestbo J., and the TORCH investigators. Salmeterol and fluticasone propionate and survival in Chronic Obstructive Pulmonary Disease. N Engl J Med 356 (2007) 775-789
46. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 59 Suppl. 1 (2004) 1-232
47. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease - 2004 update (2005). Available at: www.goldcopd.com (accessed July 7, 2006)
48. Hanania N., Ambrosino N., Calverley P., Cazzola M., Don-ner C., and Make B. Treatments for COPD. Respir Med 99 Suppl B (2005) S28-S40
49. Cazzola M., Vinciguerra A., Di Perna F., and Matera M. Early reversibility to salbutamol does not always predict bron-chodilation after salmeterol in stable chronic obstructive pulmonary disease. Respir Med 92 (1998) 1012-1016
50. Matera M., Sanduzzi A., Ponticiello A., Vatrella A., Salzillo A., and Cazzola M. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses. Respiration 72 (2005) 466-470
51. O'Donnell D., and Webb K. Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation. Am Rev Respir Dis 148 (1993) 1351-1357
52. O'Donnell D., Lam M., and Webb K. Spirometric correlates of improvement in exercise performance after anticholiner-gic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 (1999) 542-549
53. Ramirez-Venegas A., Ward J., Lentine T., and Mahler D. Salme-terol reduces dyspnea and improves lung function in patients with COPD. Chest 112 (1997) 336-340
54. Celli B., ZuWallack R., Wang S., and Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 124 (2003) 1743-1748
55. Boyd G., Morice A., Pounsford J., Siebert M., Peslis N., and Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 10 (1997) 815-821
56. Cazzola M., Matera M., Santangelo G., Vinciguerra A., Rossi F., and D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 89 (1995) 357-362
57. Aalbers R., Ayres J., Backer V., Decramer M., Lier P., Magyar P., Malolepszy J., Ruffin R., and Sybrecht G. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 19 (2002) 936-943
58. Mahler D., Donohue J., Barbee R., Goldman M., Gross N., Wisniewski M., Yancey S., Zakes B., Rickard K., and Anderson W. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 115 (1999) 957-965
59. Dahl R., Greefhorst L., Nowak D., Nonikov V., Byrne A., Thomson M., Till D., and Della C.G. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 778-784
60. Casaburi R., Mahler D., Jones P., Wanner A., San P., ZuWallack R., Menjoge S., Serby C., and Witek Jr. T. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
61. Anzueto A., Tashkin D., Menjoge S., and Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 18 (2005) 75-81
62. Vincken W., van Noord J., Greefhorst A., Bantje T., Kesten S., Korducki L., and Cornelissen P. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19 (2002) 209-216
63. Donohue J., van Noord J., Bateman E., Langley S., Lee A., Witek Jr. T., Kesten S., and Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122 (2002) 47-55
64. Brusasco V., Hodder R., Miravitlles M., Korducki L., Towse L., and Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58 (2003) 399-404
65. Sin D., McAlister F., Man S., and Anthonisen N. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 290 (2003) 2301-2312
66. Barnes P. Theophylline for COPD. Thorax 61 (2006) 742-743
67. Tashkin D., Celli B., Decramer M., Pauwels R., Menjoge S., Burkhart D., Cassino C., and Kesten S. Bronchodilator responsiveness in COPD patients enrolled in the UPLIFT trial [abstract]. Proc Am Thor Soc 2 (2005) A656
68. 2-agonists. Paediatr Respir Rev 2 (2001) 57-62
69. 3 muscarinic acetylcholine receptor regulation in the airway. Am J Respir Cell Mol Biol 26 (2002) 269-272
70. Brichetto L., Song P., Crimi E., Rehder K., and Brusasco V. Modulation of cholinergic responsiveness through the β-adrenoceptor signal transmission pathway in bovine tra-chealis. J Appl Physiol 95 (2003) 735-741
71. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 105 (1994) 1411-1419
72. D'Urzo A., De Salvo M., Ramirez-Rivera A., Almeida J., Sichletidis L., Rapatz G., and Kottakis J. In patients with COPD, treatment with a combination of formoterol and iprat-ropium is more effective than a combination of salbu-tamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 119 (2001) 1347-1356
73. Richter K., Stenglein S., Mucke M., Sieder C., Schmidtmann S., Harnest U., Weidinger G., and Magnussen H. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration 73 (2006) 414-419
74. Cazzola M., Di Marco F., Santus P., Boveri B., Verga M., Matera M., and Centanni S. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 17 (2004) 35-39
75. Cazzola M., Noschese P., Salzillo A., De Giglio C., D'Amato G., and Matera M. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular for-moterol in COPD patients. Respir Med 99 (2005) 524-528
76. Cazzola M., Centanni S., Santus P., Verga M., Mondoni M., di Marco F., and Matera M. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 98 (2004) 1214-1221
77. van Noord J., Aumann J., Janssens E., Smeets J., Ver-haert J., Disse B., Mueller A., and Cornelissen P. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 26 (2005) 214-222
78. Vogelmeier C., Harari S., Fonay K., Beier J., Overend T., Till D., Stenglein S., and Oldani V. Formoterol and tiotropium both improve lung function in stable COPD patients, with some additional benefit when given together [abstract]. Eur Respir J 28 Suppl 50 (2006) 429s
79. Di Marco F., Verga M., Santus P., Morelli N., Cazzola M., and Cen-tanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: A pilot study. Respir Med (2006) 10.1016/j.rmed.2006.03.007 [Epub ahead of print]
80. 2-agonists and corticosteroids in stable COPD. Chest 126 (2004) 220-237
81. Rabe K., Timmer W., Sagriotis A., and Viel K. Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD [abstract]. Eur Respir J 26 Suppl 49 (2005) 14s
82. Cazzola M., Andò F., Santus P., Ruggeri P., Di Marco F., San-duzzi A., and D'Amato M. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther (2006) 10.1016/j.pupt.2006.06.001 [Epub ahead of print]
83. Ferguson G., Funck-Brentano C., Fischer T., Darken P., and Reisner C. Cardiovascular safety of salmeterol in COPD. Chest 123 (2003) 1817-1824
84. FDA Public Health Advisory. Serevent Diskus (sal-meterol xinafoate inhalation powder), Advair Diskus (flu-ticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder) (2006). http://www.fda.gov/cder/drug/advisory/LABA.htm Accessed May 28, 2006
85. 2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 65 (2005) 1595-1610
86. Salpeter S., Buckley N., and Salpeter E. Meta-analysis: anti-cholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 21 (2006) 1011-1019